Estrogen Prevents Neuroprotection by Caffeine in the Mouse 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Model of Parkinson's Disease

Epidemiological studies have strongly linked caffeine consumption with a reduced risk of developing Parkinson's disease (PD) in men. Interestingly, in women, this inverse association is present only in those who have not taken postmenopausal estrogens, suggesting an interaction between the influences of estrogen and caffeine use on the risk of PD. To explore a possible biological basis for this interaction, we systematically investigated how the neuroprotective effect of caffeine is influenced by gender, ovariectomy (OVX), and then exogenous estrogen in the mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of PD. (1) Caffeine treatment produced a dose-dependent attenuation of MPTP-induced striatal dopamine loss in both young and retired breeder (RB) male, but not female, mice. (2) In female mice (both young and RB), caffeine was less potent or altogether ineffective as a neuroprotectant after sham surgery compared to OVX or after OVX plus estrogen replacement compared to OVX plus placebo treatment. (3) Estrogen treatment also prevented the protection of caffeine against dopamine loss in young male mice. (4) Consistent with the putative protective effect of estrogen, female and OVX plus estrogen mice were relatively resistant to MPTP toxicity compared to male and OVX plus placebo mice, respectively. (5) There was no overall difference in brain levels of caffeine and its metabolites between OVX plus placebo and OVX plus estrogen mice. Together, these results suggest that estrogen can occlude and thereby prevent the neuroprotective effect of caffeine in a model of PD neurodegeneration, supporting a biological basis for the interaction between estrogen and caffeine in modifying the risk of PD.

[1]  T. L. Thompson,et al.  Estrogen mediated inhibition of dopamine transport in the striatum: Regulation by Gαi/o , 2005 .

[2]  E. Bastia,et al.  Therapeutic potential of adenosine A(2A) receptor antagonists in Parkinson's disease. , 2005, Pharmacology & therapeutics.

[3]  M. Joghataie,et al.  Protective effect of caffeine against neurodegeneration in a model of Parkinson's disease in rat: behavioral and histochemical evidence. , 2004, Parkinsonism & related disorders.

[4]  M. Thun,et al.  Coffee consumption, gender, and Parkinson's disease mortality in the cancer prevention study II cohort: the modifying effects of estrogen. , 2004, American journal of epidemiology.

[5]  A. Mendelowitsch,et al.  Acute effects of 17β-estradiol on the extracellular concentration of excitatory amino acids and energy metabolites during transient cerebral ischemia in male rats , 2004, Brain Research.

[6]  T. Saleh,et al.  Estrogen attenuates neuronal excitability in the insular cortex following middle cerebral artery occlusion , 2004, Brain Research.

[7]  N. Pedersen,et al.  No evidence for heritability of Parkinson disease in Swedish twins , 2004, Neurology.

[8]  Roberta Diaz Brinton,et al.  Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease , 2004, Experimental Neurology.

[9]  E. Bézard,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease: A systematic assessment , 2004, Neurology.

[10]  F. Menniti,et al.  Repeated Estradiol Treatment Prevents MPTP-Induced Dopamine Depletion in Male Mice , 2003, Neuroendocrinology.

[11]  F. Speizer,et al.  Caffeine, postmenopausal estrogen, and risk of Parkinson’s disease , 2003, Neurology.

[12]  L. Griffiths,et al.  The measurement of adenosine and estrogen receptor expression in rat brains following ovariectomy using quantitative PCR analysis. , 2003, Brain research. Brain research protocols.

[13]  M. Schwarzschild,et al.  Caffeine's neuroprotection against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity shows no tolerance to chronic caffeine administration in mice , 2002, Neuroscience Letters.

[14]  W. Willett,et al.  Prospective study of caffeine consumption and risk of Parkinson's disease in men and women , 2001, Annals of neurology.

[15]  M. Schwarzschild,et al.  Neuroprotection by Caffeine and A2A Adenosine Receptor Inactivation in a Model of Parkinson's Disease , 2001, The Journal of Neuroscience.

[16]  D. Dluzen,et al.  Tamoxifen abolishes estrogen's neuroprotective effect upon methamphetamine neurotoxicity of the nigrostriatal dopaminergic system , 2001, Neuroscience.

[17]  D. Schaid,et al.  Smoking, alcohol, and coffee consumption preceding Parkinson’s disease , 2000, Neurology.

[18]  G. Tucker,et al.  Parkinson's disease and CYP1A2 activity. , 2000, British journal of clinical pharmacology.

[19]  C. Tanner,et al.  Association of coffee and caffeine intake with the risk of Parkinson disease. , 2000, JAMA.

[20]  M. Folan,et al.  Inhibition of Caffeine Metabolism by Estrogen Replacement Therapy in Postmenopausal Women , 1999, Journal of clinical pharmacology.

[21]  B. Fredholm,et al.  Actions of caffeine in the brain with special reference to factors that contribute to its widespread use. , 1999, Pharmacological reviews.

[22]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[23]  H. Yamazaki,et al.  Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. , 1998, Chemical research in toxicology.

[24]  J. O'Callaghan,et al.  The Impact of Gender and Estrogen on Striatal Dopaminergic Neurotoxicity , 1998, Annals of the New York Academy of Sciences.

[25]  J. Cadet,et al.  The dopamine-depleting effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in CD-1 mice are gender-dependent , 1996, Brain Research.

[26]  D. Dluzen,et al.  Estrogen Alters MPTP‐Induced Neurotoxicity in Female Mice: Effects on Striatal Dopamine Concentrations and Release , 1996, Journal of neurochemistry.

[27]  R. Tukey,et al.  Caffeine metabolism by human hepatic cytochromes P450: contributions of 1A2, 2E1 and 3A isoforms. , 1994, Biochemical pharmacology.

[28]  T. Di Paolo,et al.  Modulation by estradiol and progesterone of the GTP effect on striatal D-2 dopamine receptors. , 1993, Biochemical pharmacology.

[29]  F. Gonzalez,et al.  Biotransformation of caffeine, paraxanthine, theobromine and theophylline by cDNA-expressed human CYP1A2 and CYP2E1. , 1992, Pharmacogenetics.

[30]  J. Langston,et al.  The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: a critical reassessment , 1992, Brain Research.

[31]  S. Schenker,et al.  Impaired elimination of caffeine by oral contraceptive steroids. , 1980, The Journal of laboratory and clinical medicine.

[32]  T. L. Thompson,et al.  Estrogen mediated inhibition of dopamine transport in the striatum: regulation by G alpha i/o. , 2005, European journal of pharmacology.

[33]  D. Abernethy,et al.  Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives , 2004, European Journal of Clinical Pharmacology.

[34]  D. Inzitari,et al.  Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. , 2000, Neurology.

[35]  W. J. Brooks,et al.  Influence of sex, age and strain on MPTP-induced neurotoxicity , 1989 .

[36]  T. Di Paolo,et al.  Striatal D-2 dopamine agonist binding sites fluctuate during the rat estrous cycle. , 1988, Life sciences.